Form 4: Precigen CEO Acquires Shares Through Performance Stock Unit Vesting, Sells Shares for Tax Obligations

Precigen's CEO, Helen Sabzevari, acquired 825,000 shares of common stock through the vesting of performance stock units and sold 286,967 shares to cover tax obligations.

Summary

• Helen Sabzevari, the President and CEO of Precigen, Inc., acquired 825,000 shares of common stock on January 29, 2025.
• These shares were obtained through the vesting of performance stock units (PSUs) that were originally granted on August 28, 2024.
• The vesting was contingent upon the achievement of specific performance conditions.
• Concurrently, Ms. Sabzevari sold 286,967 shares of common stock at a price of $1.30 per share.
• This sale was to cover income tax withholding obligations related to the vesting of the PSUs.
• Following these transactions, Ms. Sabzevari beneficially owns 2,759,109 shares of Precigen common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation. The vesting of PSUs is positive, but the sale of shares for tax purposes is neutral. Overall, the sentiment is slightly positive but not significantly impactful.

Positives

• The vesting of performance stock units indicates that performance conditions were met, which is a positive sign for the company's performance.
• The CEO's increased shareholding, even after selling shares for tax purposes, demonstrates continued alignment with the company's success.

Negatives

• The sale of 286,967 shares, while for tax purposes, could be perceived negatively by some investors as a reduction in the CEO's direct holdings.

Risks

• The sale of shares by an executive, even for tax purposes, can sometimes create short-term price volatility.
• The market may interpret the sale as a lack of confidence, despite the stated reason being tax obligations.

Management Comments

• The shares were issued on settlement of the first installment of performance stock units.
• Shares were withheld to satisfy income tax withholding obligations.

Industry Context

This type of transaction is common for executives who receive stock-based compensation. The vesting of performance stock units is tied to company performance, and the subsequent sale of shares to cover taxes is a standard practice.

Comparison to Industry Standards

• Many biotechnology and pharmaceutical companies use performance-based stock units as part of executive compensation packages.
• The vesting of these units is typically tied to specific performance metrics, such as clinical trial milestones or revenue targets.
• The sale of shares to cover tax obligations is a common practice among executives in publicly traded companies, and the number of shares sold is often determined by the tax rate and the value of the vested shares.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use similar compensation structures for their executives.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign of company performance.
• The sale of shares by the CEO, even for tax purposes, could cause some short-term price fluctuations.

Key Dates

Keywords

Precigen, Helen Sabzevari, performance stock units, share acquisition, tax obligations, insider trading, SEC Form 4, executive compensation